Recent OCGN News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:27:38 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/04/2026 05:23:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 04:38:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 04:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 04:07:26 PM
- Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/04/2026 01:15:00 PM
- Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa • GlobeNewswire Inc. • 03/02/2026 12:02:00 PM
- Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/18/2026 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:59:25 PM
- Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer • GlobeNewswire Inc. • 02/09/2026 12:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2026 01:12:02 PM
- Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock • GlobeNewswire Inc. • 01/23/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 10:29:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/21/2026 10:27:56 PM
- Ocugen shares slide after company prices $22.5 million equity raise • IH Market News • 01/21/2026 03:35:56 PM
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock • GlobeNewswire Inc. • 01/21/2026 01:32:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 01:31:02 PM
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration • GlobeNewswire Inc. • 01/15/2026 01:15:00 PM
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data • GlobeNewswire Inc. • 01/13/2026 12:00:00 PM
- Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy • GlobeNewswire Inc. • 01/12/2026 11:30:00 AM
- Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference • GlobeNewswire Inc. • 01/09/2026 12:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:20:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 10:17:28 PM
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit • GlobeNewswire Inc. • 12/10/2025 02:20:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
